Valneva Se ADR (VALN)

$9.26 -0.29 (-3.04%)
Market Cap 820.60M
Revenue (ttm) 183.50M
Net Income (ttm) -13.25M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -7.22%
Debt to Equity Ratio 0.90
Volume 25,900
Avg Vol 89,750
Day's Range N/A - N/A
Shares Out 85.93M
Stochastic %K 14%
Beta 1.86
Analysts Strong Sell
Price Target $13.28

Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-a...

Industry: Biotechnology
Sector: Healthcare
Phone: 33 2 28 07 37 10
Fax: 33 2 28 07 37 11
Website: valneva.com
Address:
6 rue Alain Bombard, Saint-Herblain, France
TheCheeseWrangler
TheCheeseWrangler Oct. 27 at 5:02 PM
$VALN https://valneva.com/press-release/valneva-to-present-and-hold-investor-meetings-at-upcoming-u-s-and-european-healthcare-conferences-2/
1 · Reply
Creisi
Creisi Oct. 27 at 4:54 PM
$VALN current price means very little as the stock has virtually no volume. With such low volume, news in either direction can have major consequences on price. With Lyme Disease Clinical Trial News due this quarter; I expect a spike in buying pressure coinciding with sharp price increase; compounded by this extremely low volume of daily stock sales.
0 · Reply
OliviaEatz_
OliviaEatz_ Oct. 27 at 11:37 AM
$VALN hold ratings
0 · Reply
PickelballPaul
PickelballPaul Oct. 15 at 10:55 PM
$VALN First locally reported case of mosquito transmitted chikungunya virus in years in New York today
1 · Reply
Doozio
Doozio Oct. 15 at 9:36 PM
$VALN 👀 MAMA moar cup n handle for da 🧠 to spread TTWO 🐒🍌🧠⏰♾️
1 · Reply
Siuolman58
Siuolman58 Oct. 15 at 9:39 AM
$VALN 💎 $VALN 🔬 Chikungunya setback is baked in. Now the market’s sleeping on Lyme & Shigella upside. If VLA15 Phase III shows signs of life (or any favorable interim readout), this could rip. Accumulate this pain — small float, huge asymmetry. 🚀
0 · Reply
TheCheeseWrangler
TheCheeseWrangler Oct. 13 at 9:17 AM
$VALN €2.64 average , I've averaged down since Corona days & kept adding. Mid-2026 should be one hell of a payday 😉
0 · Reply
Siuolman58
Siuolman58 Oct. 9 at 11:03 PM
$VALN Pfizer buyout possibility?
1 · Reply
Creisi
Creisi Oct. 9 at 4:44 PM
$VALN It amazes me that no one in North America realizes how tremendous a LYME Vaccine will be come springtime. Everyone with a pet, everyone that goes to a park, hikes, camps or does any outside activity like gardening will be getting this vaccine. The market is far greater than analysts realize. I was projecting this stock to be $25 in spring of 2026. I can push that further, and see it passing $40 by June 2026, no problem whatsoever. This is perhaps the safest biopharma stock anyone can buy right now. Tremendous stock to buy, hold for June 2026, and then reap massive profits... I see you VALN and I'm loading up as much as I can.
2 · Reply
Creisi
Creisi Oct. 7 at 6:19 PM
$VALN This stock will soar past $25 come 1st quarter 2026, especially with the LYME disease Pfizer deal. Closest thing to a sure bet that there is on the market today.
0 · Reply
Latest News on VALN
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences

Oct 27, 2025, 12:45 PM EDT - 7 hours ago

Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences

Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business Updates

Oct 6, 2025, 11:35 AM EDT - 21 days ago

Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business Updates

Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ®

Sep 30, 2025, 1:00 AM EDT - 27 days ago

Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ®

Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate

Sep 3, 2025, 1:00 AM EDT - 7 weeks ago

Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate

Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday

Aug 25, 2025, 12:02 PM EDT - 2 months ago

Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday

KDP VENU

Johnson Fistel Investigates Valneva Following FDA Suspension

Aug 25, 2025, 10:43 AM EDT - 2 months ago

Johnson Fistel Investigates Valneva Following FDA Suspension

Safety Concerns Hit Valneva As Ixchiq Chikungunya Virus Vaccine Is Suspended In US

Aug 25, 2025, 10:29 AM EDT - 2 months ago

Safety Concerns Hit Valneva As Ixchiq Chikungunya Virus Vaccine Is Suspended In US

FDA suspends Valneva's chikungunya vaccine license in the U.S.

Aug 25, 2025, 1:16 AM EDT - 2 months ago

FDA suspends Valneva's chikungunya vaccine license in the U.S.

Valneva Announces FDA's Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.

Aug 25, 2025, 1:00 AM EDT - 2 months ago

Valneva Announces FDA's Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.

Valneva's Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older

Aug 18, 2025, 1:00 AM EDT - 2 months ago

Valneva's Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older

Valneva SE (VALN) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 3:20 PM EDT - 2 months ago

Valneva SE (VALN) Q2 2025 Earnings Call Transcript

Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates

Aug 12, 2025, 1:00 AM EDT - 2 months ago

Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates

Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information

Aug 7, 2025, 1:18 AM EDT - 2 months ago

Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information

AGC Biologics' Heidelberg Site Supplies Drug Substance for Phase II Studies of Valneva's Tetravalent Shigella Vaccine Candidate

Jul 29, 2025, 10:00 AM EDT - 3 months ago

AGC Biologics' Heidelberg Site Supplies Drug Substance for Phase II Studies of Valneva's Tetravalent Shigella Vaccine Candidate

Valneva Announces Lifting of European Medicines Agency's Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly

Jul 11, 2025, 11:35 AM EDT - 3 months ago

Valneva Announces Lifting of European Medicines Agency's Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly

Europe lifts restriction on Valneva's chikungunya vaccine for elderly adults

Jul 11, 2025, 8:18 AM EDT - 3 months ago

Europe lifts restriction on Valneva's chikungunya vaccine for elderly adults

Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus

Jun 26, 2025, 1:00 AM EDT - 4 months ago

Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus

Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance

Jun 25, 2025, 11:45 AM EDT - 4 months ago

Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance

UK's MHRA suspends Valneva's chikungunya vaccine for elderly

Jun 9, 2025, 10:29 AM EDT - 5 months ago

UK's MHRA suspends Valneva's chikungunya vaccine for elderly

Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®

Jun 5, 2025, 11:45 AM EDT - 5 months ago

Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®

Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update

Jun 4, 2025, 1:00 AM EDT - 5 months ago

Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update

Valneva to Participate at U.S. and European Investor Conferences in June

May 26, 2025, 11:30 AM EDT - 5 months ago

Valneva to Participate at U.S. and European Investor Conferences in June

Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States

May 12, 2025, 1:00 AM EDT - 6 months ago

Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States

Valneva SE (VALN) Q1 2025 Earnings Call Transcript

May 9, 2025, 9:47 AM EDT - 6 months ago

Valneva SE (VALN) Q1 2025 Earnings Call Transcript

Valneva SE: Still Undervalued Travel Vaccine Bet With Robust 2025 Guidance

May 8, 2025, 12:30 AM EDT - 6 months ago

Valneva SE: Still Undervalued Travel Vaccine Bet With Robust 2025 Guidance

Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly

May 7, 2025, 11:45 AM EDT - 6 months ago

Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly

Europe reviews Valneva's chikungunya vaccine after reports of serious side-effects in older people

May 7, 2025, 8:40 AM EDT - 6 months ago

Europe reviews Valneva's chikungunya vaccine after reports of serious side-effects in older people

Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 7, 2025, 1:00 AM EDT - 6 months ago

Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities

Apr 26, 2025, 1:10 PM EDT - 6 months ago

Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities

Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers

Apr 18, 2025, 4:00 AM EDT - 6 months ago

Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers

Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ®

Apr 16, 2025, 11:45 AM EDT - 6 months ago

Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ®

Brazil Approves Valneva's Mosquito-Borne Chikungunya Vaccine

Apr 14, 2025, 2:28 PM EDT - 7 months ago

Brazil Approves Valneva's Mosquito-Borne Chikungunya Vaccine

Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country

Apr 14, 2025, 11:45 AM EDT - 7 months ago

Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country

Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2

Apr 9, 2025, 1:00 AM EDT - 7 months ago

Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2

VALN Investors Have Opportunity to Join Valneva SE Fraud Investigation with the Schall Law Firm

Apr 7, 2025, 9:33 AM EDT - 7 months ago

VALN Investors Have Opportunity to Join Valneva SE Fraud Investigation with the Schall Law Firm

Valneva SE Shareholding Declaration - March 2025

Apr 3, 2025, 11:45 AM EDT - 7 months ago

Valneva SE Shareholding Declaration - March 2025

Valneva's Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above

Apr 1, 2025, 11:45 AM EDT - 7 months ago

Valneva's Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above

Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA

Mar 31, 2025, 1:00 AM EDT - 7 months ago

Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA

Valneva Renews its Sales Agreement in connection with its Existing At-the-Market (ATM) Program

Mar 26, 2025, 1:00 PM EDT - 7 months ago

Valneva Renews its Sales Agreement in connection with its Existing At-the-Market (ATM) Program

Valneva Announces Filing of 2024 Universal Registration Document and US Form 20-F

Mar 25, 2025, 2:00 AM EDT - 7 months ago

Valneva Announces Filing of 2024 Universal Registration Document and US Form 20-F

Valneva Responds to French Government's Call for Vaccine Supply of IXCHIQ® against Chikungunya Outbreak in La Réunion

Mar 24, 2025, 2:00 AM EDT - 7 months ago

Valneva Responds to French Government's Call for Vaccine Supply of IXCHIQ® against Chikungunya Outbreak in La Réunion

Valneva SE (VALN) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 8:00 PM EDT - 7 months ago

Valneva SE (VALN) Q4 2024 Earnings Call Transcript

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Stockholders to Learn More About the Investigation

Mar 20, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Stockholders to Learn More About the Investigation

Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook

Mar 20, 2025, 2:00 AM EDT - 7 months ago

Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Valneva SE (VALN) And Encourages Shareholders to Reach Out

Mar 19, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Valneva SE (VALN) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Shareholders to Learn More About the Investigation

Mar 18, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Shareholders to Learn More About the Investigation

Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Mar 17, 2025, 10:00 AM EDT - 8 months ago

Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

TheCheeseWrangler
TheCheeseWrangler Oct. 27 at 5:02 PM
$VALN https://valneva.com/press-release/valneva-to-present-and-hold-investor-meetings-at-upcoming-u-s-and-european-healthcare-conferences-2/
1 · Reply
Creisi
Creisi Oct. 27 at 4:54 PM
$VALN current price means very little as the stock has virtually no volume. With such low volume, news in either direction can have major consequences on price. With Lyme Disease Clinical Trial News due this quarter; I expect a spike in buying pressure coinciding with sharp price increase; compounded by this extremely low volume of daily stock sales.
0 · Reply
OliviaEatz_
OliviaEatz_ Oct. 27 at 11:37 AM
$VALN hold ratings
0 · Reply
PickelballPaul
PickelballPaul Oct. 15 at 10:55 PM
$VALN First locally reported case of mosquito transmitted chikungunya virus in years in New York today
1 · Reply
Doozio
Doozio Oct. 15 at 9:36 PM
$VALN 👀 MAMA moar cup n handle for da 🧠 to spread TTWO 🐒🍌🧠⏰♾️
1 · Reply
Siuolman58
Siuolman58 Oct. 15 at 9:39 AM
$VALN 💎 $VALN 🔬 Chikungunya setback is baked in. Now the market’s sleeping on Lyme & Shigella upside. If VLA15 Phase III shows signs of life (or any favorable interim readout), this could rip. Accumulate this pain — small float, huge asymmetry. 🚀
0 · Reply
TheCheeseWrangler
TheCheeseWrangler Oct. 13 at 9:17 AM
$VALN €2.64 average , I've averaged down since Corona days & kept adding. Mid-2026 should be one hell of a payday 😉
0 · Reply
Siuolman58
Siuolman58 Oct. 9 at 11:03 PM
$VALN Pfizer buyout possibility?
1 · Reply
Creisi
Creisi Oct. 9 at 4:44 PM
$VALN It amazes me that no one in North America realizes how tremendous a LYME Vaccine will be come springtime. Everyone with a pet, everyone that goes to a park, hikes, camps or does any outside activity like gardening will be getting this vaccine. The market is far greater than analysts realize. I was projecting this stock to be $25 in spring of 2026. I can push that further, and see it passing $40 by June 2026, no problem whatsoever. This is perhaps the safest biopharma stock anyone can buy right now. Tremendous stock to buy, hold for June 2026, and then reap massive profits... I see you VALN and I'm loading up as much as I can.
2 · Reply
Creisi
Creisi Oct. 7 at 6:19 PM
$VALN This stock will soar past $25 come 1st quarter 2026, especially with the LYME disease Pfizer deal. Closest thing to a sure bet that there is on the market today.
0 · Reply
Siuolman58
Siuolman58 Oct. 7 at 9:09 AM
$VALN Buy on Lyme!!!
0 · Reply
ajmore
ajmore Oct. 7 at 7:18 AM
$VALN opporrunity to buy, the new guidance hardly differs from previous one and lyme data is due.
1 · Reply
AStrokeOfLuck
AStrokeOfLuck Oct. 6 at 4:52 PM
$VALN
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 3 at 9:16 AM
$VALN Excellent article that nails exactly where VALN stands right now. So if you want to update your VALN knowledge or get acquainted with VALN, this is a must read. https://beyondspx.com/quote/VALN/analysis/valneva-s-vaccine-renaissance-lyme-catalyst-and-chikungunya-s-resilient-path-nasdaq-valn
0 · Reply
ajmore
ajmore Oct. 1 at 11:29 AM
$VALN pfizer's deal with trump, yesterday, gives pfizer 5 years exempt from tarrifs on any product they sell that is manufactured outside the US.
0 · Reply
Riderman29
Riderman29 Oct. 1 at 11:10 AM
$VALN 7% up in Europe, continue strong uptrend
0 · Reply
Papusa
Papusa Oct. 1 at 8:45 AM
$VALN Production USA or EU for Lyme?
1 · Reply
Papusa
Papusa Oct. 1 at 8:44 AM
$VALN does anyone know where will be Lyme produced? In EU or USA? In which production plant?
0 · Reply
ajmore
ajmore Oct. 1 at 7:34 AM
$VALN further thoughts on the 4 year serotype update! commercially: this makes valneva's vaccine first choice. 4 year immunogenicity is cost effective, enhances the herd immunity and lowers risks associated with repetitive vaccinations. Platform: have we got something that can go further, I mean flu vaccines... Large Pharma watching. impressive development.
0 · Reply
topstockalerts
topstockalerts Sep. 30 at 12:10 PM
$VALN setting up nicely.. 🍾
0 · Reply
G101SPM
G101SPM Sep. 30 at 11:12 AM
$VALN $11.80 ask. BUY/NEW LONG POSITION carries SPM 87.06 tag to $25.00 in midterm.
0 · Reply
DaxCo
DaxCo Sep. 30 at 10:41 AM
$VALN 💥↗️ 🔋
0 · Reply